Skip to content

    Manorama Indust.

    MANORAMA
    Fast Moving Consumer Goods·28 Apr 2025
    Management Summary

    Manorama Industries Limited delivered robust financial performance in FY25, exceeding revenue guidance with 69% YoY growth and significant margin expansion. This was driven by strong market demand, economies of scale from new fractionation capacity, and product innovation. The company is focused on global expansion and operational efficiencies, with a positive outlook for FY26 revenue and capacity utilization, though specific capex details are pending Board approval.

    Highlights

    5
    • Achieved FY25 revenue guidance of ₹771 crores, registering 69% YoY growth.

    • EBITDA grew 1.6 times YoY to ₹191 crores, with margin expanding by 870 bps to 24.8% for FY25.

    • PAT surged almost 2 times to ₹112 crores, with margin expanding by 576 bps to 14.5% for FY25.

    • Successfully commercialized 25,000 tons new fractionation capacity, increasing total to 40,000 tons per annum.

    • Established strategic global subsidiaries in West Africa, UAE, and Brazil to strengthen market presence.

    Concerns

    3
    • Capex plan for forward and backward integration projects is still in advanced drawing and planning stage, awaiting Board approval.

    • Management was evasive regarding specific contract renegotiation clauses, citing confidentiality.

    • While margins are healthy, management prefers to focus on operational excellence rather than committing to further margin expansion.

    What Changed2

    vs Q2 FY26

    Guidance items7 → 9 (+2)Risks discussed1 → 2 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹771 Cr+69%YoY
    2. 02EBITDA₹191 Cr+60%YoY
    3. 03EBITDA Margin24.8%
    4. 04PAT₹112 Cr+100%YoY
    5. 05PAT Margin14.5%

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹380 crores · 0.8x EBITDA

    Dividend

    ₹0.006/share (final)

    M&A

    Global subsidiaries in West Africa, UAE, and Brazil

    joint venture · Other

    Liquidity

    Liquidity disclosed

    Company has healthy internal accruals to fund capex.

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    Top line
    ₹1,050 crores
    High
    Revenue
    Revenue Growth (Volume-led)
    25% to 30%
    Medium
    Revenue
    Revenue Growth (Price-led)
    5% to 10%
    Medium
    Capacity
    Combined Capacity Utilization
    75% to 85%
    High
    Profitability
    EBITDA Margin
    23% to 25%
    Medium
    Working Capital
    Working Capital Days
    120-140 days
    High
    Working Capital
    Receivables Days
    30 days
    High
    Product Mix
    CBE as percentage of sales
    beyond 30%
    Medium
    Operating Expenses
    Employee Expenses
    5% to 10% jump
    Medium

    Capex plan approval and details

    next quarter
    CurrentUnder advanced drawing and planning stage, awaiting Board approval
    TargetBoard approval and detailed financial plan shared with shareholders

    Why it matters

    Clarity on future growth investments and funding strategy is crucial for long-term valuation.

    We will share a comprehensive report on these projects detailed financial plan with our esteemed shareholders through exchange filings once our management Board approves going forward our capital expenditure plan.

    How to verify

    capital_allocation.capex.fy_planned

    Risks & concerns

    2
    RiskSeverity

    Raw material price volatility and inventory management

    Raw materials are seasonal, requiring bulk procurement and stocking, which can lead to high inventory levels and potential volatility.Management acknowledged

    medium

    Impact of new capex on future margins

    Analyst questioned if immense expansion and integration could hurt margins, management stated it's too early to say.Analyst not addressed

    low

    Q&A highlights

    8

    “So related to your margin question, so this performance is a result of our continued focus on operational efficiencies, premiumization initiatives and disciplined execution. So, looking ahead, while we remain confident in the structural strength of our business model and our ability to sustain healthy margins, we prefer to stay focused on operational excellence and value creation for our shareholders.”

    Analyst sought confirmation on margin sustainability given new plant utilization, but management provided a qualitative response focusing on operational excellence rather than a direct numerical commitment.

    asked by Nitin Gosar

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Financial Performance & Growth Drivers

    Manorama Industries Limited reported robust growth in FY25, with revenue reaching ₹771 crores, a 69% year-on-year increase. This performance was attributed to strong market demand for specialty butters and fats, coupled with economies of scale from new fractionation facilities. EBITDA grew 1.6 times year-on-year to ₹191 crores, expanding the margin by 870 basis points to 24.8%. Profit After Tax (PAT) surged almost 2 times to ₹112 crores, with a PAT margin of 14.5%.

    02

    Capacity Expansion & Utilization

    The company successfully commercialized a new 25,000 tons fractionation capacity in Q2 FY25, bringing the total fractionation capacity to 40,000 tons per annum. The existing 15,000 tons facility operated at 100% utilization, while the new unit achieved 40-50% utilization for the full year, resulting in a combined utilization of 62.5% for FY25. For FY26, the company projects combined capacity utilization to increase significantly to 75-85%, aiming for greater operational efficiencies.

    03

    Global Market Expansion & Product Innovation

    Manorama Industries has expanded its global footprint by establishing strategic subsidiaries in West Africa, the UAE, and Brazil to strengthen its market presence. The company's R&D team developed new products in FY25, including various filling fats and frozen dessert applications, and is tapping into new geographies. Management noted a significant demand-supply gap in the specialty niche market globally, particularly in Latin America, which is projected to be a 25,000 to 30,000-ton market for CBE and stearin.

    04

    Margin Management & Cost Efficiency

    The company's EBITDA margin expanded by 870 basis points to 24.8% in FY25, driven by efficient cost management and operating leverage. PAT margin also saw a substantial increase of 576 basis points to 14.5%. Management emphasized a continuous focus on operational efficiencies, premiumization initiatives, and disciplined execution to sustain healthy margins. The contribution of value-added products like CBE to sales increased from 10% last year to 30% this year, further supporting margin improvement.

    05

    Working Capital & Debt Management

    Manorama Industries has trimmed its working capital days from 180 to 150 days in FY25 and aims to further reduce them to 120-140 days in FY26. Net debt stood at ₹380 crores as of March 31, 2025, primarily comprising working capital loans, with a net debt-to-equity ratio of 0.83:1. The company plans to reduce net debt going forward and aims for receivables days of around 30 days for FY26. Inventory, including raw materials and finished goods, was ₹549 crores as of March 31, 2025.

    06

    Capital Expenditure Plans

    The company has several forward and backward integration projects planned, which are currently in advanced drawing and planning stages. Management stated that a comprehensive report with detailed financial plans for these projects would be shared with shareholders once approved by the Board. These capex plans are expected to be funded through healthy internal accruals, with construction anticipated to begin this year. The company aims to start these projects within a period of less than 3 years.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.